Entry prohibited for AIDS viruses: Peptide triazole inhibitors disrupt cell-free HIV-1

Jul 08, 2011

(PhysOrg.com) -- The initial entry of HIV-1 into host cells remains a compelling yet elusive target for the development of agents to prevent infection, a critical need in the fight against the global AIDS epidemic.

A collaborative research effort led by Irwin Chaiken at Drexel University and Drexel University College of Medicine (Philadelphia, PA, USA) has demonstrated that modified peptide triazole inhibitors which specifically target the HIV-1 envelope (Env) protein gp120 can physically disrupt in the absence of host cells, and the results are reported in ChemMedChem.

The Drexel team found that under conditions similar to those at which a newly designed peptide triazole (KR13) inhibits infection of host cells by an HIV-1 pseudovirus, it also causes virus rupture and release of an internal HIV-1 protein called gag p24 when incubated with virus alone.

Both inhibition of cell infection and p24 release are enhanced substantially by the multivalent display of KR13 on gold nanoparticles.

The novel antagonist design and reported characterization data could lead to the creation of a virucide to suppress initial HIV-1 infection, viremia in infected individuals, and the spread of infection between individuals. Such agents could be used for HIV-1 microbicides and therapeutics.

These results also suggest that ligand-specific pathogen rupture may be possible for other viruses that contain metastable prefusion complexes, such as influenza, Ebola, and Dengue.

Explore further: Four billion-year-old chemistry in cells today

More information: Irwin Chaiken, Cell-Free HIV-1 Virucidal Action by Modified Peptide Triazole Inhibitors of Env gp120, ChemMedChem 2011, 6, No. 8, dx.doi.org/10.1002/cmdc.201100177

add to favorites email to friend print save as pdf

Related Stories

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

HIV isolate from Kenya provides clues for vaccine design

Jan 02, 2008

Two simple changes in its outer envelope protein could render the AIDS virus vulnerable to attack by the immune system, according to research from Kenya and the Fred Hutchinson Cancer Research Center published in PLoS Medicine.

How HIV vaccine might have increased odds of infection

Nov 03, 2008

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. A new study by a team of researchers at the Montpellier ...

Recommended for you

Building the ideal rest stop for protons

5 hours ago

Where protons, or positive charges, decide to rest makes the difference between proceeding towards ammonia (NH3) production or not, according to scientists at Pacific Northwest National Laboratory (PNNL) and ...

Cagey material acts as alcohol factory

6 hours ago

Some chemical conversions are harder than others. Refining natural gas into an easy-to-transport, easy-to-store liquid alcohol has so far been a logistic and economic challenge. But now, a new material, designed ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

positiveguy
not rated yet Jul 09, 2011
HIV positive singles face very difficult challenges when it comes to dating. They have to either date someone with HIV or disclose their HIV status. Disclosing to someone that's HIV is a terrifying task and finding someone else with HIV. POZmingle. com helps you Dating and Finding Love for HIV Positive Singles.